{"id":2823,"date":"2024-05-08T10:41:48","date_gmt":"2024-05-08T10:41:48","guid":{"rendered":"https:\/\/mmevost.wpenginepowered.com\/success-stories\/aptatargets-aptoll-es\/"},"modified":"2025-11-25T14:12:34","modified_gmt":"2025-11-25T14:12:34","slug":"aptatargets-aptoll-es","status":"publish","type":"success-stories","link":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/","title":{"rendered":"Aptatargets \u2013 ApTOLL"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico.<br \/>\nEIC Accelerator- 2,5 millones de euros<br \/>\nTipo de financiaci\u00f3n: Grant First<\/p>\n","protected":false},"featured_media":2462,"template":"","meta":{"_acf_changed":false},"flags":[102],"program":[46],"sector":[36],"class_list":["post-2823","success-stories","type-success-stories","status-publish","has-post-thumbnail","hentry","flags-es","program-instrumento-pyme-eic-accelerator","sector-salud"],"acf":{"layouts_cases":[{"acf_fc_layout":"content","content":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"content":"El ictus afecta cada a\u00f1o a 15 millones de personas en todo el mundo, y el ictus isqu\u00e9mico constituye el 87% de los casos. Es la principal causa de discapacidad en adultos y ocupa el segundo lugar mundial entre las causas de muerte. Los tratamientos de reperfusi\u00f3n actuales s\u00f3lo benefician a un 20% de los pacientes debido a la limitada ventana de tratamiento y a los estrictos criterios de elegibilidad. A pesar de los esfuerzos realizados, no se dispone de ninguna terapia para proteger el cerebro del da\u00f1o celular en pacientes con ictus.\r\n\r\n<a href=\"https:\/\/aptatargets.com\/\">AptaTargets<\/a>, una empresa biofarmac\u00e9utica espa\u00f1ola en fase cl\u00ednica especializada en tecnolog\u00eda de apt\u00e1meros, ha desarrollado <strong>ApTOLL<\/strong>, un nuevo tratamiento con un potente efecto neuroprotector para dar respuesta a esta necesidad no cubierta. ApTOLL, el primer modulador inmunitario y neuroprotector de su clase, <strong>se dirige al receptor Toll-like 4 (TLR4) con gran especificidad, bloqueando la respuesta inflamatoria en pacientes con ictus isqu\u00e9mico agudo (AIS).<\/strong>\r\n\r\nGracias al impresionante historial de ApTOLL, que reduce el da\u00f1o cerebral en un 47% y disminuye sustancialmente las tasas de mortalidad del 18% a s\u00f3lo el 4%, los pacientes pueden esperar no s\u00f3lo una mayor supervivencia, sino tambi\u00e9n mejores resultados funcionales y una mejor calidad de vida en general. El destacado potencial de esta innovaci\u00f3n le vali\u00f3 a AptaTargets un codiciado puesto entre los ganadores del competitivo instrumento de financiaci\u00f3n <a href=\"https:\/\/eic.ec.europa.eu\/eic-funding-opportunities\/eic-accelerator_en\">EIC Accelerator<\/a> en la convocatoria de noviembre de 2023. Con una <strong>subvenci\u00f3n de 2,5 millones de euros<\/strong>, AptaTargets se dispone ahora a iniciar los ensayos cl\u00ednicos de fase 2b."}},{"acf_fc_layout":"media","media":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"intro":"","section_type":"image","image":2460,"video_type":"mp4","upload_video":"","video_id":"","video_placeholder":"","video_title":"","button":null}}],"layouts":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.2 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aptatargets \u2013 ApTOLL - evolution-europe<\/title>\n<meta name=\"description\" content=\"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptatargets \u2013 ApTOLL\" \/>\n<meta property=\"og:description\" content=\"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First\" \/>\n<meta property=\"og:url\" content=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/\" \/>\n<meta property=\"og:site_name\" content=\"evolution-europe\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T14:12:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/1-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1708\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/\",\"name\":\"Aptatargets \u2013 ApTOLL - evolution-europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1-scaled-1.jpg\",\"datePublished\":\"2024-05-08T10:41:48+00:00\",\"dateModified\":\"2025-11-25T14:12:34+00:00\",\"description\":\"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/#primaryimage\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1-scaled-1.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1-scaled-1.jpg\",\"width\":2560,\"height\":1708},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/aptatargets-aptoll-es\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Success stories\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aptatargets \u2013 ApTOLL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"name\":\"evolution-europe\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\",\"name\":\"Evolution Europe\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"width\":2000,\"height\":1600,\"caption\":\"Evolution Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aptatargets \u2013 ApTOLL - evolution-europe","description":"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/","og_locale":"es_ES","og_type":"article","og_title":"Aptatargets \u2013 ApTOLL","og_description":"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First","og_url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/","og_site_name":"evolution-europe","article_modified_time":"2025-11-25T14:12:34+00:00","og_image":[{"width":2560,"height":1708,"url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/1-scaled-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/","url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/","name":"Aptatargets \u2013 ApTOLL - evolution-europe","isPartOf":{"@id":"https:\/\/evolutioneurope.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/#primaryimage"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/#primaryimage"},"thumbnailUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/1-scaled-1.jpg","datePublished":"2024-05-08T10:41:48+00:00","dateModified":"2025-11-25T14:12:34+00:00","description":"ApTOLL, un novedoso tratamiento neuroprotector, se dirige al receptor Toll-like 4 (TLR4) para reducir el da\u00f1o cerebral y las tasas de mortalidad en pacientes con ictus isqu\u00e9mico. EIC Accelerator- 2,5 millones de euros Tipo de financiaci\u00f3n: Grant First","breadcrumb":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/#primaryimage","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/1-scaled-1.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/1-scaled-1.jpg","width":2560,"height":1708},{"@type":"BreadcrumbList","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/aptatargets-aptoll-es\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/evolutioneurope.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Success stories","item":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/"},{"@type":"ListItem","position":3,"name":"Aptatargets \u2013 ApTOLL"}]},{"@type":"WebSite","@id":"https:\/\/evolutioneurope.eu\/es\/#website","url":"https:\/\/evolutioneurope.eu\/es\/","name":"evolution-europe","description":"","publisher":{"@id":"https:\/\/evolutioneurope.eu\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/evolutioneurope.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/evolutioneurope.eu\/es\/#organization","name":"Evolution Europe","url":"https:\/\/evolutioneurope.eu\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","width":2000,"height":1600,"caption":"Evolution Europe"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories\/2823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories"}],"about":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/types\/success-stories"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media\/2462"}],"wp:attachment":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media?parent=2823"}],"wp:term":[{"taxonomy":"flags","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/flags?post=2823"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/program?post=2823"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/sector?post=2823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}